Ezeprogind (AZP-2006) is an orally active neurotrophic inducer that effectively addresses the underlying factors contributing to neurodegeneration, with a broad scope extending beyond the conventional targets like Abeta protein and tau protein. Exhibiting potent neuroprotective properties, Ezeprogind is a valuable tool for studying a range of neurological disorders, including progressive supranuclear palsy (PSP), tauopathies, Alzheimer's disease, Parkinson's disease, and others.